Last reviewed · How we verify

NCT06613932

Assessment of L-PRF, Nanohydroxyapatite Combined With L-PRF Using Pulpotomy in Mature Mandibular First Molars

Recruiting now NA Last updated 26 September 2024
What this trial tests

NA trial testing pulpotomy in Irreversible Pulpitis in 45 participants. Currently enrolling.

Timeline
30 October 2023
Primary endpoint
30 October 2024
30 October 2024

Quick facts

Lead sponsorFuture University in Egypt
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment45
Start date30 October 2023
Primary completion30 October 2024
Estimated completion30 October 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Future University in Egypt

Who can join

Adults 15 to 30, any sex, with Irreversible Pulpitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Clinical and Radiographic Assessment of L-PRF, Nanohydroxyapatite material combined with L-PRF scaffold in Vital pulp Therapy. Treatments in Mandibular First Molars with Closed Apices, Randomized Controlled Trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of pulpotomy

Trials testing the same drug.

Other recruiting trials for Irreversible Pulpitis

Currently open trials in the same condition.

Other Future University in Egypt trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06613932.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing